ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "immunology"

  • Abstract Number: 1332 • ACR Convergence 2020

    Identifying the as Patient at Risk: Is Aortic Root Diameter Associated with HLA-B27?

    Milad Baniaamam1, Sjoerd C. Heslinga2, M. Louis Handoko3, Thelma C. Konings3, Otto Kamp3, Vokko P. van Halm4, J. Christiaan van Denderen1, Irene van der Horst-Bruinsma2 and Mike Nurmohamed5, 1Reade, Amsterdam, Netherlands, 2Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, 3Department of Cardiology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, 4Department of Cardiology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, 5Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands

    Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory joint disease (IJD) associated with cardiac involvement particularly aortic valve regurgitation (AVR).  AVR in AS is caused by…
  • Abstract Number: 1636 • ACR Convergence 2020

    8 Years Follow-Up of a Novel Autoinflammatory Disease: CD59 Malfunction Causes Hemolytic Anemia, Recurrent Guillain-Barre Syndrome, and Strokes in Pediatric Populations and Respond Well to Eculizumab and Pozelimab

    Dror Mevorach1 and Netanel Karbian1, 1Hadassah-University Hospital, Jerusalem, Yerushalayim, Israel

    Background/Purpose: In 2013 we have described the first patients with a novel autoinflammatory disease manifested in 4 children with recurrent Guillain-Barre syndrome and hemolytic anemia…
  • Abstract Number: 0072 • ACR Convergence 2020

    Characterizing Heterogeneity of Synovial Macrophages in Rheumatoid Arthritis Patients

    Shang-Yang Chen1, Yidan Wang2, Anna Montgomery2, Salina Dominguez2, Carla Cuda2, Gaurav Gadhvi1, Harris Perlman2 and Deborah Winter3, 1Northwestern University, Chicago, IL, 2Northwestern University, Chicago, 3Northwestern University Division of Rheumatology, Chicago, IL

    Background/Purpose: Macrophages in the synovial lining of the joint are critical players in the pathogenesis of rheumatoid arthritis (RA). While they are potent producers of…
  • Abstract Number: 0496 • ACR Convergence 2020

    A Role of Lipid-Peroxidation in Systemic Lupus Erythematosus-Associated Cardiovascular Disease

    David Patrick1, Justin van Beusecum1, Michelle Ormseth2, Leslie J. Crofford2, Sean Davies3, Sergey Dikalov1 and David Harrison1, 1Vanderbilt University Medical Center, Nashville, 2Vanderbilt University Medical Center, Nashville, TN, 3Vanderbilt University, Nashville

    Background/Purpose: In SLE, cardiovascular complications are a significant contributor to morbidity and death. Importantly, there is an increased prevalence of hypertension in SLE patients compared…
  • Abstract Number: 1401 • ACR Convergence 2020

    Disease Mutation That Weakens ZAP70 Autoinhibition Enhances Responses to Weak and Self Ligands

    Lin Shen1, Mehrdad Matloubian1, Theresa Kadlecek2 and Arthur Weiss1, 1University of California, San Francisco, San Francisco, CA, 2University of California, San Francisco, San Francisco

    Background/Purpose: ZAP70, a cytoplasmic protein tyrosine kinase, is critical for TCR signaling and T cell development. Complete loss of function of ZAP70 in humans causes…
  • Abstract Number: 1670 • ACR Convergence 2020

    Low Copy Number of Long C4 Genes Is a Genetic Risk Factor for Childhood Onset SLE (cSLE) but Is Associated with Higher Age of Disease Onset

    Fatima Barbar-Smiley1, Danlei Zhou2, Joanne Drew2, Bi Zhou2, Cagri Yildirim-Toruner2, Vidya Sivaraman3, Wael Jarjour4, Stacy Ardoin2 and Chack-Yung Yu5, 1Nationwide Children's Hospital/The Ohio State University, Columbus, OH, 2Nationwide Children's Hospital, Columbus, OH, 3Nationwide Children's Hospital, Bexley, OH, 4The Ohio State University, Columbus, OH, 5Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH

    Background/Purpose: Hypocomplementemia is a marked feature of systemic lupus erythematosus (SLE), which may be a result of consumption initiated by immune complexes between self-nuclear antigens…
  • Abstract Number: 0090 • ACR Convergence 2020

    110 Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Rheumatology Disease Unit: Fracture, Neuropathy, and Pernicious Anemia Are Clues to Recognition

    Michael Lovy1 and Andrew Dulalia1, 1Desert Oasis Healthcare, Palm Springs, CA

    Background/Purpose: Monoclonal gammopathy of undetermined significance (MGUS) has been associated with osteoporosis, neuropathy, pernicious anemia, and low vitamin B12, and may precede multiple myeloma and…
  • Abstract Number: 0511 • ACR Convergence 2020

    ERAP1-mediated Immunogenicity and Immune-phenotypes in HLA-B51+ Behçet’s Disease Point to Pathogenic CD8 T Cell Effector Responses

    Ann Cavers1, Yesim Ozguler2, Olivier Manches3, Arshed Al-Obeidi1, Hua Zhong1, Beatrix Ueberheide1, Gülen Hatemi4, Matthias Kugler1 and Johannes Nowatzky5, 1NYU School of Medicine, New York, 2Istanbul University Cerrahpaşa Medical School, Istanbul, Turkey, 3Inserm, U 1209, Grenoble, France, 4Istanbul University‒Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, Istanbul, Turkey, 5New York University School of Medicine, New York, NY

    Background/Purpose: HLA-B51 is a definite risk factor for Behçet’s disease (BD). A coding variant of ERAP1, Hap10 – with low peptide-trimming activity – vastly potentiates…
  • Abstract Number: 1402 • ACR Convergence 2020

    Galectin-3 Decreases the Activity of 4-1BB by Facilitating Its Decoy Surface Binding in Rheumatoid Arthritis

    Morten Aagaard Nielsen1, Kristian Juul-Madsen2, John Stegmayr3, Chao Gao4, Tue Wenzel Kragstrup1, Malene Hvid1, Thomas Vorup-Jensen1, Richard Cummings5, Hakon Leffler3 and Bent Deleuran1, 1Aarhus University, Aarhus, Denmark, 2Aarhus University, Aarhus, Midtjylland, Denmark, 3Lund University, Lund, Sweden, 4Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA, 5Beth Israel Deaconess Medical Center Harvard Medical School, Boston

    Background/Purpose: Orchestration of immune checkpoints is central for the outcome of immune activation, especially in patients with rheumatoid arthritis (RA). We have previously shown that…
  • Abstract Number: 1747 • ACR Convergence 2020

    Brain fMRI Predicts Responses to Certolizumab Pegol in RA. an International, Multi-center, Randomized, Double-blind, Placebo-controlled Trial (PreCePRA)

    Juergen Rech1, Hannah Schenker2, Koray Tascilar1, Melanie Hagen2, Arnd Kleyer1, David Simon1, Larissa Valor Mendez2, Verena Schoenau3, Jutta Prade4, Marina Sergeeva4, Mageshvar Sulvakumar5, Sandra Strobelt4, Laura Konerth4, Frank Behrens6, Christoph Baerwald7, Stephanie Finzel8, Reinhard Voll9, Axel Hueber10, Julie Roesch11, Eugen Feist12, José A. P. da Silva13, Arnd Doerfler11, Nemanja Damjanov14, Andreas Hess15 and Georg Schett16, 1Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 2Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, 3Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, 4Institute for Experimental Pharmacology, Erlangen, Germany, 5Insitute for Experimental Pharmacology , Fau Erlangen-Nürnberg, Erlangen, Germany, 6CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, 7Uniklinik Leipzig, Medizinische Klinik III - Bereich Rheumatologie, Leipzig, Germany, 8Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, 9Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freibrug, 10Section Rheumatology, Sozialstiftung Bamberg, Bamberg, Germany, 11Abteilung für Neuroradiologie, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, 12Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, 139.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, 14University of Belgrade Medical School, Belgrade, Serbia, 15Institute for Experimental Pharmacology, Erlangen, 16Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany

    Background/Purpose: Personalization of RA treatment is not optimal due to lack of predictors. We previously demonstrated in RA patients that central nervous system (CNS) pain…
  • Abstract Number: 0195 • ACR Convergence 2020

    Epidemiology and Characteristics of Incident Rheumatoid Arthritis in Persons with and Without HIV

    Jennifer Hanberg1, Kathleen Akgun2, Liana Fraenkel3, Evelyn Hsieh2 and Amy Justice4, 1Yale University School of Medicine; West Haven VA, Boston, MA, 2Yale University School of Medicine; West Haven VA, New Haven, CT, 3Yale School of Medicine; West Haven VA; Berkshire Medical Center, Lenox, MA, 4Yale University School of Medicine; Yale School of Public Health; West Haven VA, West Haven, CT

    Background/Purpose: Rheumatoid arthritis (RA) is the most common chronic inflammatory arthritis, affecting 1-2% of the population. Estimates of the incidence of RA in patients with…
  • Abstract Number: 0753 • ACR Convergence 2020

    Synovial Tissue Histopathology Findings in Early RA. Is It Useful? Analysis of the Belgian CAP48 Cohort

    Stéphanie de Montjoye1, Tatiana Sokolova1, Emilie Sapart1, Bernard Lauwerys2, Stéphanie Dierckx3, Christine Galant4, Laurent Meric de Bellefon1, Adrien Nzeusseu Toukap5, Clément Triaille6 and Patrick Durez7, 1Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 2Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 3Rheumatology, CHU Mont-Godinne, Mont Godinne, Belgium, 43Pathology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, 51Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium, 6Rheumatology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, 7Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium

    Background/Purpose: Rheumatoid arthritis is a heterogeneous disease with different clinical presentation and prognostic factors including the immune process in the synovium. The development of ultrasound-guided…
  • Abstract Number: 1409 • ACR Convergence 2020

    Lack of Conventional Acinar Cells in the Salivary Gland Following Anti PD-L1 and anti-PD-1 Immune Checkpoint Inhibitor Therapy

    Sarah Pringle1, Bert van der Vegt1, Xiaoyan Wang1, Nico van Bakelen1, Arjan Vissink1, Frans Kroese2 and Hendrika Bootsma2, 1UMCG, Groningen, 2University Medical Centre Groningen, Groningen, Netherlands

    Background/Purpose: Salivary glands (SGs) can be damaged by immune checkpoint inhibitor (ICI) therapy. In patients with ICI-induced SG dysfunction, 60% progress to fulfill the ACR-EULAR…
  • Abstract Number: 1750 • ACR Convergence 2020

    Longitudinal Change in the Central Nervous System Pain Response After Treatment with Certolizumab or Placebo. a Post-hoc Analysis from the Pre-CEPRA Trial

    Juergen Rech1, Hannah Schenker2, Koray Tascilar1, Melanie Hagen2, Larissa Valor Mendez2, Verena Schoenau3, Marina Sergeeva4, Jutta Prade4, Mageshvar Sulvakumar5, Laura Konert6, Arnd Kleyer1, David Simon1, Sandra Strobelt4, Frank Behrens7, Christoph Baerwald8, Stephanie Finzel9, Reinhard Voll10, Axel Hueber11, Eugen Feist12, Julie Roesch13, José A. P. da Silva14, Arnd Doerfler13, Nemanja Damjanov15, Andreas Hess16 and Georg Schett17, 1Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 2Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, 3Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, 4Institute for Experimental Pharmacology, Erlangen, Germany, 5Insitute for Experimental Pharmacology, FAU Erlangen-Nuremberg, Erlangen, Germany, 6Institute for Experimental Pharmacology, FAU Erlangen-Nürnberg, Erlangen, 7CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, 8Uniklinik Leipzig, Medizinische Klinik III - Bereich Rheumatologie, Leipzig, Germany, 9Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, 10Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freibrug, 11Section Rheumatology, Sozialstiftung Bamberg, Bamberg, Germany, 12Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, 13Abteilung für Neuroradiologie, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, 149.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, 15Belgrade University School of Medicine, Belgrade, Serbia, 16Institute for Experimental Pharmacology, Erlangen, 17Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany

    Background/Purpose: Biologicals - bring a hope of recovery or amelioration to people suffering from RA, but only half of the patients respond to such treatment.…
  • Abstract Number: 0207 • ACR Convergence 2020

    Upadacitinib Monotherapy in Methotrexate-naïve Patients with Rheumatoid Arthritis: Results at 72 Weeks

    Ronald van Vollenhoven1, Tsutomu Takeuchi2, Maureen Rischmueller3, Ricardo Blanco4, Ricardo Xavier5, Mark Howard6, Alan Friedman6, Yanna Song7 and Vibeke Strand8, 1Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, 2Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, 3The Queen Elizabeth Hospital and Univ of Adelaide, St Peters, South Australia, Australia, 4Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 5Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Rio Grande do Sul, Rio Grande do Sul, Brazil, 6AbbVie Inc., North Chicago, IL, 7AbbVie Inc., North Chicago,, IL, 8Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA

    Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, demonstrated significant improvements in signs, symptoms, and structural inhibition as monotherapy vs methotrexate (MTX) in a randomized, controlled…
  • « Previous Page
  • 1
  • …
  • 29
  • 30
  • 31
  • 32
  • 33
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology